Cargando…
Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
Imatinib mesylate is the leading compound to treat chronic myeloid leukemia (CML) and other cancers, through its inhibition of Bcr-Abl tyrosine kinases. However, resistance to imatinib develops frequently, particularly in late-stage disease and has necessitated the development of new Bcr-Abl inhibit...
Autores principales: | Arvaniti, Katerina, Papadioti, Anastasia, Kinigopoulou, Maria, Theodorou, Vassiliki, Skobridis, Konstantinos, Tsiotis, Georgios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302748/ https://www.ncbi.nlm.nih.gov/pubmed/28250386 http://dx.doi.org/10.3390/proteomes2030363 |
Ejemplares similares
-
Cytotoxicity of Isoxazole Curcumin Analogs on Chronic Myeloid Leukemia-Derived K562 Cell Lines Sensitive and Resistant to Imatinib
por: Feriotto, Giordana, et al.
Publicado: (2023) -
Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells
por: Prado-Carrillo, Omar, et al.
Publicado: (2022) -
Time-series analysis in imatinib-resistant chronic myeloid leukemia K562-cells under different drug treatments
por: Zhao, Yan-hong, et al.
Publicado: (2017) -
Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence
por: Drullion, C, et al.
Publicado: (2012) -
Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)